SARC Clinical Trials

Every day, our community of researchers, investigators, scientists, sarcoma centers, and biotech and pharmaceutical companies are working together in the development and support of clinical trials (studies). A list of SARC trials is provided here with a brief description and patient accrual status. Additionally, the National Institutes of Health provides an online registry and results database of clinical studies conducted around the world.

patient seated waiting to receive treatment

Active SARC Trials

SU2C-SARC032

A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

TYPE OF SARCOMA: Soft Tissue Sarcoma of the Extremity
DRUG: Pembrolizumab
ACCRUAL STATUS: Recruiting

See Details

SARC041

Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

TYPE OF SARCOMA: Advanced Dedifferentiated Liposarcoma
DRUG: Abemaciclib
ACCRUAL STATUS: Not yet recruiting

See Details

SARC038

A Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

TYPE OF SARCOMA: Osteosarcoma
DRUG: Regorafenib, Nivolumab
ACCRUAL STATUS: Recruiting

See Details

SARC037

A Phase I Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3’-Deoxy-3’-18F Fluorothymidine (18F-FLT) Imaging

TYPE OF SARCOMA: Ewing Sarcoma
DRUG: Trabectedin and Irinotecan
ACCRUAL STATUS: Recruiting

See Details

SARC033

A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma

TYPE OF SARCOMA: Epithelioid Hemangioendothelioma
DRUG: Trametinib
ACCRUAL STATUS: Not recruiting

See Details

SARC031

A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors

TYPE OF SARCOMA: Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)
DRUG: Selumetinib in Combination with Sirolimus
ACCRUAL STATUS: Recruiting

See Details

SARC028

A phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas

TYPE OF SARCOMA: Undifferentiated Pleomorphic Sarcoma and Poorly Differentiated/Dedifferentiated Liposarcoma
DRUG: Pembrolizumab
ACCRUAL STATUS: Not Recruiting

See Details

SARC024

A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

TYPE OF SARCOMA: Refractory Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcomas, Rhabdomyosarcoma, Mesenchymal Chondrosarcoma
DRUG: Regorafenib
ACCRUAL STATUS: Recruiting

See Details